Adicet Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ACET Nasdaq 8731 https://www.adicetbio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Adicet Bio Inc

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Dec 30th, 2022 9:43 pm
Shareholders in Adicet Bio (NASDAQ:ACET) have lost 49%, as stock drops 22% this past week - Dec 20th, 2022 1:23 pm
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) - Dec 10th, 2022 3:00 pm
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) - Dec 2nd, 2022 12:00 pm
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit - Nov 30th, 2022 9:00 pm
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer - Nov 29th, 2022 12:00 pm
Adicet Bio Third Quarter 2022 Earnings: US$0.53 loss per share (vs US$0.44 loss in 3Q 2021) - Nov 11th, 2022 10:24 am
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates - Nov 8th, 2022 9:10 pm
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Nov 7th, 2022 1:00 pm
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) - Nov 3rd, 2022 1:00 pm
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference - Nov 1st, 2022 11:00 am
Calculating The Intrinsic Value Of Adicet Bio, Inc. (NASDAQ:ACET) - Oct 23rd, 2022 12:39 pm
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting - Oct 5th, 2022 12:00 pm
We're Hopeful That Adicet Bio (NASDAQ:ACET) Will Use Its Cash Wisely - Sep 26th, 2022 10:26 am
Adicet Bio to Present at Upcoming Investor Conferences - Sep 7th, 2022 8:10 pm
The Consensus EPS Estimates For Adicet Bio, Inc. (NASDAQ:ACET) Just Fell Dramatically - Aug 16th, 2022 10:16 am
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates - Aug 10th, 2022 11:00 am
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting - Jun 6th, 2022 11:00 am
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL) - May 26th, 2022 9:00 pm
Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit - May 15th, 2022 12:21 pm